Report date: Wednesday, July 29, 2026 (after market close) | Call: 4:00 PM ET (webcast via investor.aligntech.com)
ALGN shares closed at $175.63 on July 28, 2026 — up from ~$156 at the start of the year but well off the February high near $197.50, reflecting a choppy year driven by macro anxiety, tariff/geopolitical noise, and mixed North American demand. Sell-side sentiment is split: some trackers show a roughly neutral consensus (median PT ~$175), while others (TipRanks, Yahoo/Barchart) show a more constructive average target near $206–$208, implying high-single-digit to ~18% upside, with 10 "Strong Buy," 4 "Hold," and 1 "Moderate Sell" ratings among covering analysts. The broader narrative: Wall Street wants to see discretionary dental spending inflect before getting more aggressive.
Consensus for the quarter is tracking essentially in line with management's own guidance: revenue near $1.05 billion (~3.8–3.9% y/y growth) and non-GAAP EPS in the $2.63–$2.64 range, up from $2.58 in Q1'26 and $2.49 in Q2'25. ALGN has beaten Street EPS estimates in three of the last four quarters.
On the Q1'26 call (April 29), CFO John Morici laid out Q2 guidance: - Worldwide revenue of $1.04–$1.06 billion, up ~3–5% y/y - Clear Aligner volume up sequentially and y/y; ASP flat sequentially and y/y - Systems & Services revenue up sequentially - GAAP operating margin ~16.4%; non-GAAP operating margin ~21.5%
Management also reaffirmed full-year 2026 guidance: revenue growth of 3–4%, Clear Aligner volume growth in the mid-single digits, GAAP operating margin "slightly below 18.0%" (a ~400bp y/y improvement), and non-GAAP operating margin of ~23.7% (a 100bp y/y improvement), with capex of $125–150 million.
Q1 was a clean beat-and-raise-tone quarter that sets a constructive backdrop:
"We're pleased to report another better-than-expected quarter in Q1. Clear Aligner volumes from both the GAAP and non-GAAP operating margins exceeded our outlook." Total revenue reached $1.04 billion, "up 6.2% year-over-year driven primarily by high clear Aligner volumes and increased ASPs. Clear Aligner shipments reached a record 686,000 cases, increasing 6.7% year-over-year, reflecting double-digit growth across our international businesses, and continued stability in North America."
Non-GAAP operating margin expanded sharply — "operating margin for the first quarter was 21.5%, up 2.5 points year-over-year" — as restructuring benefits and a mix shift toward lower-cost aligner configurations flowed through. Non-GAAP EPS of $2.58 was up 21% y/y.
The recurring storyline: international strength, North America softness. "Americas Q1 Clear Aligner volumes increased year-over-year, reflecting very strong double-digit growth in Latin America, partially offset by a modest but stable year-over-year decline in North America." EMEA and APAC both posted record first-quarter shipments with double-digit growth, including China, India, Korea, Japan and Taiwan. When pressed on the U.S. gap, CEO Joe Hogan was blunt: "I'd say broadly, I was actually anticipating this question, Jeff, is that it's broadly a macro of the way I look at it versus here in the rest of the world."
DSOs continue to be the standout U.S./global channel: "Dental and Orthodontic Service Organizations continue to be force multipliers in every region, driving global double-digit Clear Aligner volume growth during the quarter." DSO volumes represented roughly a quarter of total global volume in Q1, while "the retail channel continued to be mixed, particularly in the United States, where our doctor customers reported less patient traffic during the quarter."
1. North America inflection (or lack thereof). This has been the multi-quarter swing factor. Investors will want to know whether U.S. retail/GP traffic stabilized further into Q2, and whether initiatives like the Doctor Subscription Program (DSP), Healthcare Finance Direct (patient financing, now live in 4,000+ U.S. offices), and Treatment Planning Services are translating into case-start acceleration rather than just engagement metrics.
2. Middle East conflict impact — did it materialize? Management built explicit prudence into the Q2 guide: "there is uncertainty and the potential for adverse impacts on patient traffic, consumer demand and shipping and freight resulting from ongoing military action in the Middle East... Given the ongoing uncertainty, we have taken a prudent approach in our second quarter outlook by assuming some impact on both Clear Aligner and scanner demand." On the call, CFO Morici sized the EMEA/Middle East exposure as "in the Middle East part of our numbers to the company is in the single digits" and noted impact was minimal through March. The broader macro read-through matters too — economists have been cutting global consumer-spending forecasts given the conflict's effect on energy prices and household purchasing power, a dynamic that could pressure discretionary categories like elective orthodontics if it persists.
3. Margin trajectory and cadence. Management guided to a step-up in profitability in the back half after a roughly flat sequential Q2, driven by continued cost-structure benefits from 2025 restructuring actions, manufacturing productivity, and mix shift toward lower-cost, higher-margin configurations (e.g., "Zero AA"/no-refinement products). Watch for confirmation that the 2H ramp is on track and any incremental color on second-half assumptions.
4. ASP and mix. Management guided FY26 ASP down 1–2% y/y on continued shift to lower-priced products/countries, partially offset by FX and price increases; Q1's $1,250 ASP was flat sequentially into Q2 guidance. Any surprise here (positive or negative) would move estimates.
5. Systems & Services / iTero. Q1 iTero revenue was soft sequentially (seasonal) but management guided S&S revenue up sequentially in Q2. "the total installed base of active scanners exceeded 125,000 globally" with continued mix shift to lower-priced scanner configurations (PC-based, leasing, rental) — watch for updates on Lumina full-system adoption vs. the wand-upgrade cycle that drove 2025 strength.
6. China commentary. China had a record Q1 with double-digit growth, but Hogan cautioned against extrapolating: "I think anybody in the business has to be careful of using the word normal in China... It's a very dynamic marketplace... It's the most competitive market in the world."
7. Zero-AA / DSP momentum. These lower-cost, margin-accretive product configurations are scaling but were explicitly kept out of full-year guidance as anything more than a modest contributor — representing a source of potential upside if adoption accelerates faster than expected.
Several developments since the April call haven't yet been addressed in a quarterly update and are likely to draw analyst questions:
Align completed its $200 million buyback tranche (Aug 2025–Jan 2026, ~1.4 million shares at an average of $143.85) and announced a further $200 million repurchase over a six-month window starting on/about May 1, 2026, leaving $800 million available under the broader $1 billion authorization from April 2025. Balance sheet remains solid with ~$1.06 billion in cash as of Q1'26 and Q1 free cash flow of $120.3 million.
Align enters this print with genuine positive momentum — record international volumes, DSO strength, and visible margin expansion from 2025's restructuring — set against a still-soft, macro-driven North American retail/GP channel and a fresh layer of geopolitical (Middle East) and regulatory (EU antitrust) uncertainty that management has explicitly flagged as reasons for guidance prudence. The bar looks achievable (guidance and Street estimates are closely aligned around $1.05B revenue and ~$2.63 non-GAAP EPS), so the more important signals will be: (1) whether North America shows any green shoots, (2) whether the Middle East drag was smaller or larger than the "prudent" assumption baked into Q2 guidance, (3) confirmation of the expected second-half margin ramp, and (4) management's initial characterization of the EU antitrust probe. A clean beat with reassuring commentary on these fronts, absent new negative developments in the EU case, would likely be well received given how much caution is already priced into sell-side sentiment; a miss or incremental negative disclosure on the antitrust front would compound existing macro concerns.